Loading...
•
Jun 30, 2023
Lineage Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Lineage Cell Therapeutics reported a net loss of $5.2 million, or $0.03 per share, for the second quarter ended June 30, 2023. Total revenues were $3.2 million, and total operating expenses were $8.1 million. Cash, cash equivalents, and marketable securities totaled $45.9 million as of June 30, 2023.
Lineage continued to execute across multiple fronts, advancing clinical and preclinical cell transplant programs and supporting alliances.
The company focused on its partnership with Roche and Genentech and continued support for the Phase 2a clinical study of OpRegen.
Lineage reported positive clinical results from a Phase 1 study of VAC2 in non-small cell lung cancer with Cancer Research UK.
The company is focused on making progress across its pipeline while maintaining a commitment to disciplined spending.
Forward Guidance
Lineage expects its cash, cash equivalents, and marketable securities to support planned operations into Q4 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...